Recent News

• 09.18.2025 - TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry Conference
• 09.18.2025 - TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry Conference
• 09.09.2025 - Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
• 09.09.2025 - Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
• 08.07.2025 - Vistagen Therapeutics Fiscal Year 2026 First Quarter Corporate Update Conference Call
• 08.07.2025 - Vistagen Therapeutics Fiscal Year 2026 First Quarter Corporate Update Conference Call
• 08.07.2025 - Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update
• 08.07.2025 - Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update
• 07.31.2025 - Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025
• 07.31.2025 - Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025

Recent Filings

• 09.08.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.07.2025 - 8-K Current report
• 08.07.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.07.2025 - EX-99.1 EX-99.1
• 07.28.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 07.28.2025 - DEF 14A Other definitive proxy statements